Corvair vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Corvair

by AliveCor

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

Corvair by AliveCor is designed for broad, immediate diagnostic interpretation of resting ECGs, providing 35 cardiac determinations to assist healthcare professionals. In contrast, Tempus ECG-AF is a specialized predictive tool that analyzes 12-lead ECGs to identify older patients at risk of developing new-onset atrial fibrillation within the next 12 months. Therefore, while both leverage AI for ECG analysis, their distinct focus areas—general diagnosis versus specific future risk prediction—make them suitable for different clinical objectives.

Choose Corvair if…

Choose Corvair if your healthcare facility requires comprehensive, AI-powered assistance for the immediate interpretation of resting diagnostic ECGs. This tool is ideal for clinicians needing rapid analysis across 35 cardiac determinations, including both rhythm and morphology, to support their diagnostic confidence in a broad range of cardiac conditions.

View Corvair →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary goal is to proactively identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months. This solution is specifically designed for predictive risk assessment, enabling earlier identification and follow-up for a defined older patient population without pre-existing AF.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Corvair	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	Cloud, Mobile App	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Corvair

Corvair (Tool A) offers a more streamlined data acquisition process by requiring only 4 ECG leads for analysis, compared to Tempus ECG-AF (Tool B) which analyzes 12-lead ECG recordings. This simpler lead requirement can enhance ease of use and efficiency for healthcare professionals during patient assessment.

Clinical Value

Corvair

Corvair (Tool A) provides a broader diagnostic utility by offering 35 cardiac determinations, covering both rhythm and morphology, to assist in interpreting resting ECGs. While Tempus ECG-AF (Tool B) offers valuable predictive risk for AF, Corvair's comprehensive diagnostic scope provides more immediate and diverse clinical applicability for a wider range of cardiac conditions.

Pricing & Value

Tempus ECG-AF

Although both tools require contacting the vendor for specific pricing, Tempus ECG-AF (Tool B) explicitly highlights available CMS reimbursement (CPT 0764T and CPT 0765T). This established reimbursement pathway significantly enhances its value proposition for healthcare providers by offering a clear mechanism for cost recovery and financial viability.

Enterprise Readiness

Tempus ECG-AF

Both tools demonstrate strong foundational enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. However, Tempus ECG-AF (Tool B) explicitly states its deployment as a 'software solution, integrated into healthcare facility systems,' suggesting a more direct and potentially smoother integration into existing complex hospital IT infrastructures and clinical workflows.

Innovation

Tempus ECG-AF

Tempus ECG-AF (Tool B) demonstrates higher innovation through its predictive capability to identify patients at increased risk of developing atrial fibrillation/flutter within the next 12 months. This forward-looking application of AI for proactive disease management offers a distinct and potentially more impactful advancement in patient care compared to Corvair's (Tool A) broader diagnostic assistance, even with its 4-lead analysis.

Support & Docs

Tie

Both AliveCor (Tool A) and Tempus AI (Tool B) provide clear channels for customer support, including phone and email contacts. AliveCor mentions user manuals and FAQs on its support page, while Tempus refers to a 'Document Library.' Without more specific details on the depth, quality, or accessibility of these resources, it is not possible to definitively distinguish between the two.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Corvair	Tempus ECG-AF
Name	Corvair	Tempus ECG-AF
Company	AliveCor	Tempus AI, Inc.
Primary Purpose/Detection Focus	Assists healthcare professionals in interpreting resting diagnostic ECGs with 35 cardiac determinations (14 rhythm, 21 morphology).	Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
ECG Lead Requirement	Requires only 4 ECG leads for analysis	Analyzes 12-lead ECG recordings
Target Patient Population/Use Case	Assists healthcare professionals in interpreting resting diagnostic ECGs.	Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

Videos

Demos, reviews, and walkthroughs featuring Corvair and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications and target patient populations for Corvair and Tempus ECG-AF?

Corvair by AliveCor is an AI ECG analysis system that assists healthcare professionals in interpreting resting diagnostic ECGs with 35 cardiac determinations, intended for the general population. In contrast, Tempus ECG-AF is an AI-based algorithm specifically designed to analyze 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, excluding those with pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

What are the differences in ECG lead requirements and compatibility for each tool?

Corvair analyzes 10-second ECGs and requires only 4 ECG leads for analysis, compatible with standard diagnostic-bandwidth ECG recordings using wet Ag/AgCl electrodes. Tempus ECG-AF, on the other hand, analyzes 12-lead ECG recordings and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.

What kind of output or results do these AI tools provide?

Corvair provides 35 cardiac determinations, including 14 rhythm and 21 morphology analyses, to assist healthcare professionals in interpreting resting diagnostic ECGs. Tempus ECG-AF detects signs associated with new onset Atrial Fibrillation (AF) within 12 months for its specified patient population, with results interpreted in conjunction with other diagnostic information and clinical history.

Is there any specific reimbursement information available for either tool?

Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90, effective January 1, 2025. The provided information for Corvair states pricing is to 'contact vendor' and does not mention specific reimbursement details.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Corvair or Tempus ECG-AF

Backers

Who funded each tool's parent company.